American Bio Medica Corporation (ABMC) Stock Analysis

American Bio Medica Corporation (ABMC) Healthcare & Pipeline Overview

American Bio Medica Corporation specializes in rapid drug detection tests, offering a range of immunoassay solutions for urine and oral fluid analysis. Operating in the medical diagnostics sector, the company serves diverse markets including rehabilitation, pain management, and workplace drug testing across the US, Europe, and Asia Pacific.

What Is the Investment Thesis for ABMC?

American Bio Medica Corporation operates in the niche market of rapid drug detection, which presents both opportunities and challenges. The company's negative gross margin of -21.1% and profit margin of -154.4% indicate significant operational inefficiencies that need to be addressed. Growth catalysts include expanding its product line and penetrating new geographic markets, particularly in the Asia Pacific region. However, the company's small size, with only 16 employees, and limited financial resources pose risks to its ability to compete effectively and scale its operations. Investors should closely monitor the company's ability to improve its financial performance and capitalize on growth opportunities in the drug testing market.

Based on FMP financials and quantitative analysis

ABMC Key Highlights

Market capitalization of $0.00B indicates a micro-cap company with limited trading liquidity.

• Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
• Gross margin of -21.1% highlights significant challenges in cost management and pricing strategy.
• Profit margin of -154.4% indicates substantial losses relative to revenue.
• Beta of -0.12 suggests the stock is less volatile than the overall market.

Who Are ABMC's Competitors?

ABMC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ABMC's Key Strengths?

Specialized product line of rapid drug detection tests.

• Established presence in rehabilitation, pain management, and government markets.
• Contract manufacturing capabilities.
• Proprietary OralStat drug test for oral fluid analysis.

What Are ABMC's Weaknesses?

Small company size with limited resources (16 employees).

• Negative gross and profit margins.
• Limited geographic reach compared to larger competitors.
• Dependence on the drug testing market.

What Could Drive ABMC Stock Higher?

Potential new contracts with government agencies for drug testing services.

• Expansion of distribution network in the Asia Pacific region.
• Development and launch of new rapid drug detection tests.

What Are the Key Risks for ABMC?

Financial-distress signal — its Altman Z-Score of -44.22 sits in the distress zone (elevated bankruptcy risk).

• Increased competition from larger diagnostic companies.
• Regulatory changes affecting the drug testing market.
• Negative gross and profit margins impacting financial stability.
• Limited financial resources hindering growth initiatives.
• Low liquidity due to OTC market trading.

What Are the Growth Opportunities for ABMC?

• Expansion into international markets, particularly in the Asia Pacific region, where demand for drug testing is growing due to increasing urbanization and industrialization. This expansion requires strategic partnerships and regulatory approvals, but could significantly increase revenue streams. The global drug testing market is projected to reach $8.9 billion by 2027.
• Development of new drug testing products and technologies to address emerging drug threats and evolving customer needs. This includes expanding the range of detectable substances and improving the accuracy and speed of testing. Innovation in this area can provide a competitive edge and attract new customers. The market for advanced drug testing technologies is expected to grow at a CAGR of 7.5% over the next five years.
• Strengthening relationships with key customers in the rehabilitation, pain management, and government sectors to secure long-term contracts and increase sales volume. This involves providing customized solutions and excellent customer service. Building strong customer loyalty can create a stable revenue base. The rehabilitation and drug treatment market is estimated at $42 billion annually.
• Leveraging contract manufacturing services to generate additional revenue streams and diversify the company's business model. This involves utilizing existing manufacturing capabilities to produce diagnostic tests for other companies. Expanding contract manufacturing can improve capacity utilization and profitability. The global contract manufacturing market for medical devices is projected to reach $118 billion by 2028.
• Exploring opportunities in the infectious disease testing market to diversify the product portfolio and address a broader range of healthcare needs. This includes developing rapid tests for common infectious diseases and partnering with healthcare providers to offer comprehensive testing solutions. Diversification can reduce reliance on the drug testing market and create new growth avenues. The global infectious disease diagnostics market is expected to reach $27 billion by 2027.

What Threats Does ABMC Face?

• Intense competition from larger diagnostic companies.
• Regulatory changes affecting the drug testing market.
• Economic downturn impacting demand for drug testing services.
• Emergence of new drug threats requiring updated testing methods.

What Are ABMC's Competitive Advantages?

• Specialized expertise in lateral flow immunoassay technology.
• Established relationships with key customers in target markets.
• Proprietary product line of rapid drug detection tests.
• Contract manufacturing capabilities providing a diversified revenue stream.

What Does ABMC Do?

American Bio Medica Corporation, established in 1986 and based in Kinderhook, New York, focuses on developing, manufacturing, and selling rapid drug detection tests. Originally named American Micro Media, Inc., the company rebranded in 1992 to reflect its focus on biomedical solutions. Its core business revolves around lateral flow immunoassay technology, enabling the immediate detection of drugs in urine and oral fluids. The company's product line includes Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II, which detect varying panels of drugs. American Bio Medica also offers OralStat, a drug test designed for oral fluid analysis, available in private-labeled versions. Beyond its proprietary products, the company distributes complementary products for substance abuse detection and infectious disease testing. Additionally, American Bio Medica provides contract manufacturing, assembly, and packaging services to other diagnostic companies. The company serves a diverse clientele, including rehabilitation centers, pain management clinics, government agencies, and workplace drug testing programs, with operations spanning the United States, Europe, and the Asia Pacific regions.

What Products and Services Does ABMC Offer?

• Manufactures rapid drug screening tests for urine samples.
• Produces drug testing cups that detect multiple drugs simultaneously.
• Offers drug tests in cassette platforms for point-of-care testing.
• Provides oral fluid drug tests for non-invasive drug detection.
• Distributes products for detecting substances of abuse.
• Offers products to detect certain infectious diseases.
• Provides contract manufacturing, assembly, and packaging services for diagnostic companies.

How Does ABMC Make Money?

• Manufacturing and selling rapid drug detection tests.
• Distributing complementary products for substance abuse and infectious disease detection.
• Providing contract manufacturing services to other diagnostic companies.
• Generating revenue through direct sales to rehabilitation centers, pain management clinics, government agencies, and workplaces.

What Industry Does ABMC Operate In?

American Bio Medica Corporation operates within the medical diagnostics industry, specifically focusing on rapid drug testing. The market is driven by increasing concerns about substance abuse, workplace safety regulations, and the need for quick and reliable drug detection methods. The competitive landscape includes larger diagnostic companies and specialized players offering similar testing solutions. American Bio Medica's success depends on its ability to differentiate its products, maintain regulatory compliance, and effectively serve its target markets.

Who Are ABMC's Key Customers?

• Rehabilitation and drug treatment centers.
• Pain management clinics.
• Government agencies.
• Employment and workplace drug testing programs.

The most recent 10 insider filings for American Bio Medica Corporation break down as 2 sales and 8 purchases. On net that is roughly 200K shares acquired (about $54K) — insiders putting money in tends to read as conviction.

Return on equity for American Bio Medica Corporation stands at 85.9%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.21 means current liabilities exceed short-term assets, a liquidity point worth watching.

American Bio Medica Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -44.22 places it in the distress zone, a signal of elevated financial risk.

Company Profile

American Bio Medica Corporation operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Kinderhook, US. The company is led by CEO Jean Neff. ABMC has traded publicly since 1997.

ABMC Financials

ABMC Latest News

What Investors Ask About American Bio Medica Corporation (ABMC) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources